Brontictuzumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameBrontictuzumab
Drug Alias NameOMP-52M51Anti-Notch-1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionNeurogenic locus notch homolog protein 1 inhibitorsImmunomodulators
TargetsNeurogenic locus notch homolog protein 1
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOncomed Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOncomed Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursColorectal NeoplasmsLymphoma

Other Information

ATC CodeN/A
Related LinksWikipedia